315 related articles for article (PubMed ID: 33179150)
1. Development of [
Ghai A; Zheleznyak A; Mixdorf M; O'Neal J; Ritchey J; Rettig M; DiPersio J; Shokeen M; Achilefu S
Eur J Nucl Med Mol Imaging; 2021 May; 48(5):1302-1311. PubMed ID: 33179150
[TBL] [Abstract][Full Text] [Related]
2. Preclinical Development of CD38-Targeted [
Ghai A; Maji D; Cho N; Chanswangphuwana C; Rettig M; Shen D; DiPersio J; Akers W; Dehdashti F; Achilefu S; Vij R; Shokeen M
J Nucl Med; 2018 Feb; 59(2):216-222. PubMed ID: 29025987
[TBL] [Abstract][Full Text] [Related]
3. Light-Induced Radiosynthesis of
Klingler S; Fay R; Holland JP
J Nucl Med; 2020 Jul; 61(7):1072-1078. PubMed ID: 31924725
[TBL] [Abstract][Full Text] [Related]
4. Immuno-PET Imaging of CD30-Positive Lymphoma Using 89Zr-Desferrioxamine-Labeled CD30-Specific AC-10 Antibody.
Rylova SN; Del Pozzo L; Klingeberg C; Tönnesmann R; Illert AL; Meyer PT; Maecke HR; Holland JP
J Nucl Med; 2016 Jan; 57(1):96-102. PubMed ID: 26514172
[TBL] [Abstract][Full Text] [Related]
5. Zirconium-89 labeled panitumumab: a potential immuno-PET probe for HER1-expressing carcinomas.
Bhattacharyya S; Kurdziel K; Wei L; Riffle L; Kaur G; Hill GC; Jacobs PM; Tatum JL; Doroshow JH; Kalen JD
Nucl Med Biol; 2013 May; 40(4):451-7. PubMed ID: 23454247
[TBL] [Abstract][Full Text] [Related]
6. A radiopharmaceutical [
Tang Y; Hu Y; Liu W; Chen L; Zhao Y; Ma H; Yang J; Yang Y; Liao J; Cai J; Chen Y; Liu N
Nucl Med Biol; 2019 Mar; 70():23-31. PubMed ID: 30826708
[TBL] [Abstract][Full Text] [Related]
7. CD38-targeted Immuno-PET of Multiple Myeloma: From Xenograft Models to First-in-Human Imaging.
Ulaner GA; Sobol NB; O'Donoghue JA; Kirov AS; Riedl CC; Min R; Smith E; Carter LM; Lyashchenko SK; Lewis JS; Landgren CO
Radiology; 2020 Jun; 295(3):606-615. PubMed ID: 32255416
[TBL] [Abstract][Full Text] [Related]
8. CD46-Targeted Theranostics for PET and 225Ac-Radiopharmaceutical Therapy of Multiple Myeloma.
Wadhwa A; Wang S; Patiño-Escobar B; Bidkar AP; Bobba KN; Chan E; Meher N; Bidlingmaier S; Su Y; Dhrona S; Geng H; Sarin V; VanBrocklin HF; Wilson DM; He J; Zhang L; Steri V; Wong SW; Martin TG; Seo Y; Liu B; Wiita AP; Flavell RR
Clin Cancer Res; 2024 Mar; 30(5):1009-1021. PubMed ID: 38109209
[TBL] [Abstract][Full Text] [Related]
9. What is the Best Radionuclide for Immuno-PET of Multiple Myeloma? A Comparison Study Between
Bailly C; Gouard S; Guérard F; Chalopin B; Carlier T; Faivre-Chauvet A; Remaud-Le Saëc P; Bourgeois M; Chouin N; Rbah-Vidal L; Tripier R; Haddad F; Kraeber-Bodéré F; Bodet-Milin C; Chérel M
Int J Mol Sci; 2019 May; 20(10):. PubMed ID: 31137758
[TBL] [Abstract][Full Text] [Related]
10. Advancing
Wuensche TE; Stergiou N; Mes I; Verlaan M; Schreurs M; Kooijman EJM; Janssen B; Windhorst AD; Jensen A; Asuni AA; Bang-Andersen B; Beaino W; Dongen GAMS; Vugts DJ
Theranostics; 2022; 12(16):7067-7079. PubMed ID: 36276653
[TBL] [Abstract][Full Text] [Related]
11. Total-Body PET and Highly Stable Chelators Together Enable Meaningful
Berg E; Gill H; Marik J; Ogasawara A; Williams S; van Dongen G; Vugts D; Cherry SR; Tarantal AF
J Nucl Med; 2020 Mar; 61(3):453-460. PubMed ID: 31562219
[TBL] [Abstract][Full Text] [Related]
12. A comparison of DFO and DFO* conjugated to trastuzumab-DM1 for complexing
Cho H; Al-Saden N; Lam H; Möbus J; Reilly RM; Winnik MA
Nucl Med Biol; 2020; 84-85():11-19. PubMed ID: 31931305
[TBL] [Abstract][Full Text] [Related]
13. Positron-Emission Tomography of HER2-Positive Breast Cancer Xenografts in Mice with
Al-Saden N; Lam K; Chan C; Reilly RM
Mol Pharm; 2018 Aug; 15(8):3383-3393. PubMed ID: 29957952
[TBL] [Abstract][Full Text] [Related]
14. CD4
Kristensen LK; Fröhlich C; Christensen C; Melander MC; Poulsen TT; Galler GR; Lantto J; Horak ID; Kragh M; Nielsen CH; Kjaer A
Theranostics; 2019; 9(26):8221-8238. PubMed ID: 31754392
[TBL] [Abstract][Full Text] [Related]
15. 89Zr-DFO-J591 for immunoPET of prostate-specific membrane antigen expression in vivo.
Holland JP; Divilov V; Bander NH; Smith-Jones PM; Larson SM; Lewis JS
J Nucl Med; 2010 Aug; 51(8):1293-300. PubMed ID: 20660376
[TBL] [Abstract][Full Text] [Related]
16. In Vitro and In Vivo Characterization of
Allen KJH; Jiao R; Li J; Beckford-Vera DR; Dadachova E
Molecules; 2022 Oct; 27(19):. PubMed ID: 36235126
[No Abstract] [Full Text] [Related]
17. Visualizing Galectin-3 Binding Protein Expression with ImmunoPET.
Keinänen O; Sarrett SM; Delaney S; Rodriguez C; Dayts EJ; Capone E; Sauniere F; Ippoliti R; Sala G; Iacobelli S; Zeglis BM
Mol Pharm; 2023 Jun; 20(6):3241-3248. PubMed ID: 37191353
[TBL] [Abstract][Full Text] [Related]
18. Development of a novel long-lived immunoPET tracer for monitoring lymphoma therapy in a humanized transgenic mouse model.
Natarajan A; Habte F; Gambhir SS
Bioconjug Chem; 2012 Jun; 23(6):1221-9. PubMed ID: 22621257
[TBL] [Abstract][Full Text] [Related]
19. Site-specifically labeled
Kristensen LK; Christensen C; Jensen MM; Agnew BJ; Schjöth-Frydendahl C; Kjaer A; Nielsen CH
Theranostics; 2019; 9(15):4409-4420. PubMed ID: 31285769
[TBL] [Abstract][Full Text] [Related]
20. Comparison of the octadentate bifunctional chelator DFO*-pPhe-NCS and the clinically used hexadentate bifunctional chelator DFO-pPhe-NCS for
Vugts DJ; Klaver C; Sewing C; Poot AJ; Adamzek K; Huegli S; Mari C; Visser GWM; Valverde IE; Gasser G; Mindt TL; van Dongen GAMS
Eur J Nucl Med Mol Imaging; 2017 Feb; 44(2):286-295. PubMed ID: 27573793
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
